000			a
999			_c15915 _d15915
003			OSt
005			20220106145211.0
008			220106b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_915370 _a Bavaskar, Sunil R
245			_aFlortaucipir (18F) is a Radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging to image the brain: A Review
250			_aVol.11(1), Jan-Mar
260			_aRaipur _bAsian Pharma Press _c2021
300			_a60-62p
520			_aFlortaucipir F-18, also known as 18F-T807 and 18F-AV-1451, is a small indole molecule synthesized with a radioactive fluorine isotope. It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease. After crossing the blood-brain barrier, flortaucipir F-18 binds to aggregated tau protein, a hallmark of Alzheimer's disease whose incidence correlates well with disease progression. Although flortaucipir F-18 displays low levels of background binding throughout the brain, it does display off-target binding to monoamine oxidase MAO-A and MAO-B, as well as to regions containing high levels of melanin, neuromelanin, and iron It was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain[1,2,3]
650		0	_94639 _aPHARMACEUTICS
700			_97592 _aBhurat, Mayur R.
773	0		_tAsian journal of pharmaceutical research _x2231-5683 _dRaipur Asian Pharma Press
856			_uhttps://asianjpr.com/AbstractView.aspx?PID=2021-11-1-12 _yClick here
942			_2ddc _cAR